Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N10: Reduced Therapy for High-Risk Neuroblastoma
NCT06528496Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2024
- Primary completion
- Jul 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06528496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528496.